ຂໍ້ມູນເພີ່ມເຕີມ ― Lao

Acanthosis nigricans ເປັນການສະແດງອອກທາງຜິວໜັງຂອງອາການທີ່ຕິດພັນ. ມັນມັກຈະປາກົດຢູ່ບໍລິເວນຜິວໜັງເຊັ່ນ: ຄໍ, ຂີ້ແຮ້, ກະດູກ, ກອງແດນ, ຫນັງ, ແລະພື້ນທີ່ອື່ນ, ເບິ່ງຄືວ່າເປັນຈຸດດ່າງດຳທີ່ມີຂອບບໍ່ຊັດເຈນ. ສະພາບນີ້ມັກຈະກ່ຽວຂ້ອງກັບພະຍາດເບົາຫວານແລະການຕໍ່ຕ້ານອິນຊູລິນ, ແຕ່ໃນກໍລະນີທີ່ຫາຍາກ, ມັນສາມາດຊີ້ໃຫ້ເຫັນເຖິງມະເຮັງພາຍໃນຮ່າງກາຍ. ມັນອາດຈະສະແດງອອກຈາກບັນຫາຮໍໂມນ ຫຼືຈາກການກິນຢາສະເພາະເຊັ່ນ: ຢາກລຸກສູງ (systemic glucocorticoids) ແລະ ຢາກັບການກິນອອກກະສິດ (oral contraceptives).
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.

Acanthosis nigricans (AN) ແມ່ນສະພາບຜິວໜັງທົ່ວໄປທີ່ກ່ຽວຂ້ອງກັບບັນຫາສຸຂະພາບຕ່າງໆເຊັ່ນ: insulin resistance (ການຕໍ່ຕ້ານ insulin), diabetes mellitus (ພະຍາດເບົາຫວານ), obesity (ໂລກອ່ວນ), hormone disorders (ພະຍາດຮໍໂມນ), ບັນຫາຮໍໂມນ, ແລະ drug reactions (ປະຕິກິລິຍາຕໍ່ຢາ). ການປິ່ນປົວ AN ແມ່ນສຸມໃສ່ການແກ້ໄຂບັນຫາສຸຂພາບທີ່ຕິດພັນ. ໃນເບື້ອງຕົ້ນ, ທ່ານຫມໍກວດເບິ່ງອາການຂອງການຕໍ່ຕ້ານ insulin (insulin resistance), ທີ່ປະກອບມີ obesity (ໂລກອ່ວນ), dyslipidemia (cholesterol ສູງ), hypertension (ຄວາມດັນເລືອດສູງ), ແລະ type 2 diabetes mellitus (ພະຍາດເບົາຫວານປະເພດ 2). ທ່ານຫມໍມັກຈະສັ່ງໃຫ້ topical retinoids ເປັນທາງເລືອກການປິ່ນປົວທໍາອິດ, ເຊິ່ງສາມາດຊ່ວຍໃຫ້ຜິວຫນັງຫນາແຫນ້ນ. ຢ່າງໃດກໍ່ຕາມ, ພວກມັນອາດຈະບໍ່ແກ້ໄຂ hyperpigmentation (ຄວາມມືດຂອງຜິວຫນັງ). ທາງເລືອກການປິ່ນປົວອື່ນໆ (salicylic acid, podophyllin, urea, calcipotriol) ຍັງຕ້ອງການໃຊ້ເລື້ອຍໆ.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.